Argatroban use in heparin-induced thrombocytopenia

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 11, 2008, Pages 1963-1967

  Boggio, Lisa N ^a   Oza, Veeral M ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Argatroban; Heparin induced thrombocytopenia; Thrombin inhibitor

Indexed keywords

ARGATROBAN; COUMARIN; DANAPAROID; HEPARIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN INHIBITOR;

ANTIBODY BLOOD LEVEL; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; CLINICAL TRIAL; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DOSE LIVER FUNCTION RELATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; EMBOLISM PREVENTION; GANGRENE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIMB DISEASE; LOW DRUG DOSE; PROTHROMBIN TIME; RECOMMENDED DRUG DOSE; SIDE EFFECT; THROMBOEMBOLISM; THROMBOSIS;

ANTICOAGULANTS; CLINICAL TRIALS AS TOPIC; HEPARIN; HUMANS; LIVER; PIPECOLIC ACIDS; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 49649109565     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.11.1963     Document Type: Article

References (30)

1. Surgeon General's Workshop on Deep Vein Thrombosis. May 2006. Available from: surgeongeneral.gov
2. Reilly RF. The pathophysiology of immune-mediated heparin-induced thrombocytopenia. Semin Dial 2003;16(1):54-60
3. Warkentin TE. Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/ anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia. Transfus Med Rev 1996;10(4):249-58
4. Brieger DB, Mak KH, Kottke-Marchant K, et al. Heparin-induced thrombocytopenia. J Am Coll Cardiol 1998;31(7):1449-59
5. McKeage K, Plosker GL. Argatroban. Drugs 2001;61(4):515-22; discussion 523-4
6. Cleveland KW. Argatroban, a new treatment option for heparin-induced thrombocytopenia. Crit Care Nurse 2003;23(6):61-6
7. Greinacher A, Eichler P, Lubenow N, et al. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000;96(3):846-51
8. Company TM. Angiomax prescribing information. Parsippany, NJ; 2007
9. Pharmaceuticals B. Refludan prescribing information; 2004
10. Glaxo-Smith-Kline. Argartoban prescribing information; 2007
11. Okamoto S. Hijikata A. Kikumoto R, et al. Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereo-structure of its hydrophobic carboxamide portion. Biochem Biophys Res Commun 1981;101(2):440-6
12. Kikumoto R, Tamao Y, Tezuka T, et al. Selective inhibition of thrombin by (2R,4R)-4-methyl-1-[N2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl+++) sulfonyl]-l-arginyl)]-2-piperidinecarboxylic acid. Biochemistry 1984;23(1):85-90
13. Berry CN, Girardot C, Lecoffre C, et al. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin. Thromb Haemost 1994;72(3):381-6
14. Hantgan RR, Jerome WG, Hursting MJ. No effect of clot age or thrombolysis on argatroban's inhibition of thrombin. Blood 1998;92(6):2064-74
15. Swan SK, St Peter JV. Lambrecht LJ, et al. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects. Pharmacotherapy 2000;20(7):756-70
16. Izawa OKM, Komatsu T, Iida S. Pharmacokinetic studies of argatroban (MD-805) in human: concentrations of argatroban and its metabolites in plasma, urine and feces during and after drip intravenous infusion. Jpn Pharmacol Ther 1986;14:251-63
17. Nagasawa HFK, Hada M, Takahashi E, et al. Phase one study of synthetic anti-thrombin agent (MD-805) single and multiple administration studies. Jpn J Clin Pharmacol Ther 1981;12:359-75
18. Clarke RJ, Mayo G, FitzGerald GA, et al. Combined administration of aspirin and a specific thrombin inhibitor in man. Circulation 1991;83(5):1510-8
19. Walenga JM, Fasanella AR, Iqbal O, et al. Coagulation laboratory testing in patients treated with argatroban. Semin Thromb Hemost 1999;25(Suppl 1):61-6
20. Sheth SB, DiCicco RA, Hursting MJ, et al. Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin. Thromb Haemost 2001;85(3):435-40
21. Hiatt BK, MacFarlane DE, Hursting MJ. Transitioning from argatroban to warfarin in heparin-induced thrombocytopenia: an analysis of outcomes in patients with elevated International Normalized Ratio (INR). J Thromb Thrombolysis 2005;19(3):183-8
22. Smythe MA, Warkentin TE, Stephens J, et al. Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia. Am J Hematol 2002;71:50-2
23. Walenga JMKM, Lewis BE, Pifarre R. Relative heparin-induced thrombocytopenic potential of low molecular weight heparins and new antithrombotic agents. Clin Appl Thromb Hemostasis 1996;2(Suppl 1):S21-7
24. Song X, Huhle G, Wang L, et al. Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin. Circulation 1999;100(14):1528-32
25. Eichler P, Friesen HJ, Lubenow N, et al. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood 2000;96(7):2373-8
26. Harenberg J, et al. Re-exposure to recombinant (r)-hirudin in antihirudin antibody-positive patients with a history of heparin-induced thrombocytopenia. Br J Haematol 2000;109(2):360-3
27. Lewis BE, WD, Zehnder JL, Barton JC; for the ARG-911/915/915x Investigators. Argatroban reexposure in patients with heparin-induced thrombocytopenia [abstr]. Blood 2000a;96(Part 1):52a
28. Lewis BCM, Moses J, Matthai W; for the ARG-216/310/311 Investigators. Argatroban anticoagulation during initial and repeat percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Am J Cardiol 2000b;86(Suppl 8A):14i
29. Soff GA, S-B. Pers Commun; Dec 27th 2007
30. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103(14):1838-43